Haag Florian, Gylstorff Severin, Bujok Jasmin, Pech Maciej, Relja Borna
Experimental Radiology, Department of Radiology and Nuclear Medicine, Otto-von-Guericke-University, 39120 Magdeburg, Germany.
Research Campus STIMULATE, Otto-von-Guericke-University, 39120 Magdeburg, Germany.
Cancers (Basel). 2024 Aug 12;16(16):2832. doi: 10.3390/cancers16162832.
Hepatocellular carcinoma (HCC) is the largest subgroup of primary liver tumors. Ablative therapies, such as selective internal radiation therapy (SIRT), are used in late stages for patients with unresectable liver metastases and no response to other therapies. CCL2 (C-C motif chemokine ligand 2) is a potent monocyte chemoattractant. It is associated with tumor progression and metastasis. The role of circulating CCL2 as a biomarker in HCC undergoing selective internal radiation therapy remains unclear.
A total of 41 patients (8 female, 33 male) suffering from HCC and undergoing SIRT were enrolled. Pre- and post-therapy changes in circulating CCL2 levels were determined by bead-based immunoassay and compared with clinical laboratory parameters and patient data.
A total of 32 patients exhibited survival beyond 60 days. It was observed that levels of CCL2 correlated with scores indicating a higher likelihood of non-survival and with the severity of the disease. Moreover, a significant inverse correlation was discovered between CCL2 levels and the survival of patients over 60 days in relation to counts of leukocytes, granulocytes, monocytes, and C-reactive protein.
CCL2 may serve as a potential marker for patient survival after SIRT. The prediction of which HCC patients are likely to benefit from SIRT may be helpful in guiding therapeutic management.
肝细胞癌（HCC）是原发性肝肿瘤中最大的亚组。消融治疗，如选择性体内放射治疗（SIRT），用于治疗不可切除的肝转移且对其他治疗无反应的晚期患者。CCL2（C-C基序趋化因子配体2）是一种有效的单核细胞趋化剂。它与肿瘤进展和转移有关。循环CCL2作为接受选择性体内放射治疗的HCC生物标志物的作用尚不清楚。
共纳入41例患有HCC并接受SIRT治疗的患者（8例女性，33例男性）。通过基于磁珠的免疫测定法测定治疗前后循环CCL2水平的变化，并与临床实验室参数和患者数据进行比较。
共有32例患者存活超过60天。观察到CCL2水平与提示非存活可能性较高的评分以及疾病严重程度相关。此外，在CCL2水平与60天以上患者的生存之间，发现与白细胞、粒细胞、单核细胞计数和C反应蛋白存在显著的负相关。
CCL2可能作为SIRT治疗后患者生存的潜在标志物。预测哪些HCC患者可能从SIRT中获益，可能有助于指导治疗管理。
